Peregrine Pharmaceuticals Inc.s in-depth stock price analysis indicates that the stock price has rallied 13.9% in the past 12 Weeks but analyzing the 6 month chart of the stock, the price of the stock has managed to drop negative and it has dropped down to -0.7% . Looking at the past 52 week period, the stock price is down -60.39% . Relative price strength is a important factor used by wealth management firms while investing in stocks since the indicator compares the stock performance with the overall market. The relative price strength of Peregrine Pharmaceuticals Inc. has a negative value of -26.66 compared to overall market performance. Peregrine Pharmaceuticals Inc. (NASDAQ:PPHM) has climbed 13.79% in the past week and advanced 22.97% in the last 4 weeks. In the past week, the company has outperformed the S&P 500 by 12.87% and the outperformance has advanced to 20.77% for the last 4 weeks period.
Peregrine Pharmaceuticals Inc. (NASDAQ:PPHM) stock ended Friday session in the red zone in a volatile trading. The stock closed down 0.0015 points or 0.42% at $0.3565 with 3,758,304 shares getting traded. Post opening the session at $0.38, the shares hit an intraday low of $0.345 and an intraday high of $0.38 and the price was in this range throughout the day. The company has a market cap of $92 million and the number of outstanding shares has been calculated to be 257,141,530 shares. The 52-week high of Peregrine Pharmaceuticals Inc. (NASDAQ:PPHM) is $1.12 and the 52-week low is $0.282.
Peregrine Pharmaceuticals Last issued its quarterly earnings results on Dec 12, 2016. The company reported $-0.02 EPS for the quarter. Analyst had a consensus estimate of $-0.02. The company had revenue of $23.40 million for the quarter, compared to analysts expectations of $17.99 million. The companys revenue was up 146.3% compared to the same quarter last year. During the same quarter in the previous year, the company posted $-0.07 EPS.
Peregrine Pharmaceuticals, Inc. is a biopharmaceutical company with a portfolio of innovative product candidates in clinical trials for the treatment of cancer and hepatitis C virus infection. The company is pursuing three separate clinical trials in cancer and HCV infection with its lead product candidate bavituximab and Cotara. Peregrine also has in-house manufacturing capabilities through its wholly owned subsidiary Avid Bioservices, Inc., which provides development and bio-manufacturing services for both Peregrine and outside customers.